| Prev Close | 88.58 |
| Open | 88.85 |
| Day Low/High | 88.81 / 89.56 |
| 52 Wk Low/High | 74.97 / 96.31 |
| Volume | 1.11M |
| Avg Volume | 2.05M |
Novartis AG (NVS)
90.10
1.50
1.70
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.55B |
| Market Cap | 223.92B |
| EPS | 5.50 |
| P/E Ratio | 16.46 |
| Div & Yield | 1.84 (2.07%) |
Latest News
Tilray Stock Gains Ahead of Highly Anticipated Earnings Release
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
Should You Go for the 'Easy Money' in Novartis?
NVS been in an uptrend the past twelve months.
Jim Cramer: Looking for Netflix Action? Don't Be a Hero
Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.
Market Yin and Yang
We've got some push-pull in pre-market trading as moves lower in Netflix , Limelight Networks , United Rentals , SAP and Alcoa duel with Apple , which is moving higher pre-market, and positive moves in Novartis , eBay , Phillip Morris International ...
China's Drugmakers Under Scrutiny After Stanford Admissions Scandal
Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?
Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point
Let's review the charts and indicators this morning.
Jim Cramer: The Forbidden City of Stock Sectors
Now, we know that if we got any sort of truce in the trade war, with the exception of the financials, these hated sectors would be loved.
Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space
Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.
Stock of the Day - Tilray
Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...
Tilray Stock Lights Up as Partnerships Obscure Profitability Problem
The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.
Jim Cramer: How to Win Now, With or Without China
If we can advance without China then who the heck knows where we can go with it.
Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings
Medicine is a slow business and I view Gilead Sciences as a hold for now.
Excuse Me, Would You Like Some Cannabis With Your Coffee?
CBD could make coffee an around the clock craze.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet
Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
Novartis Stock Is Poised to Rise Another 15% From Here
The stock's performance has been impressive in the past three months.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Tilray Is Now a Top-Tier Cannabis Play
I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.
Tilray Stock Burns Higher With Anheuser-Busch Beverage Deal
Pot stock partnerships are a gateway to gains for cannabis investors.
Tilray Stock Higher Ahead of First Post-Legalization Earnings Release
Tilray will have a lot to tackle this evening.
A Reckless Fed: Market Recon
It's time for the central bank to show the same level of concern for their misplaced aggression.
Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG
Tesla will pay $20 million as part of the settlement with Elon Musk paying another $20 million.
Novartis Is Ready to Rally From a Large Base Pattern
Let's check out the latest charts and indicators for some technical guidance.
Jim Cramer: Reefer Madness
Tilray's a disruptive company for many industries.
Gilead's Earnings Fail to Impress
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
